Contact
searchSearch
HMP Global
Login
Quiz

ADC Performance in HR-Positive, HER2-Negative Metastatic Breast Cancer

08/21/2025

Related Content

Seth Wander, MD, PhD
Videos
Evaluating Oral SERDs in HR-Positive, HER2-Negative Breast Cancer
03/18/2026
Seth Wander MD, PhD
Seth Wander, MD, PhD, discusses whether emerging oral SERDs differ meaningfully in HR-positive, HER2-negative breast cancer.
Seth Wander, MD, PhD, discusses whether emerging oral SERDs differ meaningfully in HR-positive, HER2-negative breast cancer.
Seth Wander, MD, PhD, discusses...
03/18/2026
Oncology
Sami Diab, MD
Videos
Updated NCCN Guidelines Strengthen Support for Breast Cancer Index® in Extended Endocrine Therapy Decision-Making
01/23/2026
Sami Diab, MD
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent...
01/23/2026
Oncology
Joseph Sparano, MD
Conference Coverage
Multimodal AI Model Strengthens Prognostic Accuracy for Late Distant Recurrence in HR-Positive, HER2-Negative Early Breast Cancer
12/18/2025
Joseph Sparano, MD
Joseph Sparano, MD, discusses new findings from the TAILORx multimodal AI analysis, which identified that multimodal AI models, particularly the ICM+ model, significantly outperformed traditional models for predicting late distant recurrence...
Joseph Sparano, MD, discusses new findings from the TAILORx multimodal AI analysis, which identified that multimodal AI models, particularly the ICM+ model, significantly outperformed traditional models for predicting late distant recurrence...
Joseph Sparano, MD, discusses...
12/18/2025
Oncology
Aditya Bardia, MD
Conference Coverage
Giredestrant Improves Survival Outcomes in ER-Positive, HER2-Negative Early-Stage Breast Cancer
12/18/2025
Aditya Bardia, MD
Aditya Bardia, MD, discusses results from the phase 3 lidERA trial showing giredestrant significantly improved invasive disease-free survival compared to standard endocrine therapy for patients with ER-positive, HER2-negative early-stage...
Aditya Bardia, MD, discusses results from the phase 3 lidERA trial showing giredestrant significantly improved invasive disease-free survival compared to standard endocrine therapy for patients with ER-positive, HER2-negative early-stage...
Aditya Bardia, MD, discusses...
12/18/2025
Oncology

Recent News

FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
FDA Approval
FDA Approves Vepdegestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
05/01/2026
Emily Estrada
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase...
05/01/2026
Oncology
News
Varegacestat Advances Toward FDA Review in Desmoid Tumors
04/30/2026
Stephanie Holland
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase...
04/30/2026
Oncology
News
Nirogacestat Improves Outcomes Across Prognostic Subgroups of Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis...
04/30/2026
Oncology
News
FOG-001 Shows Early Activity in Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study...
04/30/2026
Oncology
News
Bireociclib Plus Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer
04/30/2026
Emily Estrada
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3...
04/30/2026
Oncology
News
Romiplostim Reduces the Need for Dose Modifications in Chemotherapy-Induced Thrombocytopenia
04/30/2026
Emily Estrada
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE...
04/30/2026
Oncology
News
Tri-Weekly Cisplatin Matches Weekly Dosing With Better Tolerability in Cervical Cancer
04/30/2026
Stephanie Holland
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO...
04/30/2026
Oncology
FDA Alerts
FDA Grants Breakthrough Therapy Designation to TERN-701 in Ph-Positive Chronic Myeloid Leukemia
04/30/2026
Stephanie Holland
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2...
04/30/2026
Oncology
News
HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma
04/29/2026
Emily Estrada
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study...
04/29/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use